e-602
palleon pharma
['e-602']
enjoyed presenting 1st in human, 1st in class, novel bi-sialidase e-602. glyco-biology is tremendously interesting w big implications for cancer #immunotherapy. e-602 showed on-target immune activation &amp; cytokines cw mech. slides below #glycotime #aacr23 
Immunotherapy of Cancer • Melanoma • Phase I Clinical Trials •  Lab: @ImmunoTiil • Disclosures: https://t.co/p3vwd3bi9o